S. pneumoniae Penicillin Susceptibility United States 1979200014

11/8/01


Click here to start


Table of Contents

PPT Slide

S. pneumoniae Penicillin Susceptibility United States 1979200014

Temporal Trends in Macrolide Resistance Among Invasive Streptococcus pneumoniae Isolates and Macrolide Use USA 1993-1999

S. pneumoniae: susceptibility of middle ear fluid isolates in two time periods*

H. influenzae: susceptibility of middle ear fluid isolates in two time periods*

Acute otitis media studies in children

PPT Slide

Outpatient clinical studies in respiratory tract infections

Sample sizes required to detect differences between antibacterial drugs for acute otitis media Comparison of bacteriologic vs clinical outcomes in trials of two drugs (half the patients would be in each arm of a study)

Azithromycin in AOM: clinical outcome at end of therapy studies

PPT Slide

Using pharmacokinetics and pharmacodynamics to predict bacterial efficacy

Evaluating antibacterial efficacy using pharmacokinetics and pharmacodynamics

Patterns of antibacterial activity

Relationship between time above MIC and efficacy in animal infection models infected with S. pneumoniae

Relationship between time above MIC and bacterial eradication with ?-lactams in otitis media

Microbiologic outcome of middle ear fluid in experimental acute otitis media in chinchillas due to non-typeable Hemophilus influenzae F E Babl, S I Pelton, Z Li. Experimental Acute Otitis Media Due to Non-typable Haemophilus Influenzae: Comparison of High and Low Dose Azithromycin with Placebo. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, August 2000 and submitted for publication

PPT Slide

PPT Slide

PPT Slide

S. pneumoniae and H. influenzae pneumonia in rats: ED50 based on ?3 log10 reduction in cfu/lung

S. pneumoniae and H. influenzae pneumonia in rats: ED50 based on ?3 log10 reduction in cfu/lung

S. pneumoniae and H. influenzae pneumonia in rats: ED50 based on ? 3 log10 reduction in cfu/lung

PPT Slide

Pharmacodynamic vs NCCLS breakpoints (g/mL)

Susceptibility of Isolates at PK/PD and NCCLS breakpoints

S. pneumoniae: oral agents approved or recommended for AOM with ?90% of recent US strains susceptible at NCCLS or PK/PD breakpoints (g/mL)

H. influenzae: oral agents approved or recommended for AOM with ?90% of recent US strains susceptible at NCCLS or PK/PD breakpoints (g/mL)

Azithromycin MICs (S. pneumoniae and H. influenzae)

Azithromycin MICs (S. pneumoniae and H. influenzae)

Conclusions: Antibacterial choice for empiric use in acute otitis media

Author: Michael Jacobs